125 related articles for article (PubMed ID: 36579364)
1. Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.
Xia L; Guo J; E H; Zhang W; Huang Y; Zhang L; Zhao D; Xie D; Wu C; Hou L
Histopathology; 2023 Apr; 82(5):691-703. PubMed ID: 36579364
[TBL] [Abstract][Full Text] [Related]
2. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
3. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
[TBL] [Abstract][Full Text] [Related]
4. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
6. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
[TBL] [Abstract][Full Text] [Related]
7. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
9. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
12. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.
Yamane Y; Ishii G; Goto K; Kojima M; Nakao M; Shimada Y; Nishiwaki Y; Nagai K; Kohrogi H; Ochiai A
J Thorac Oncol; 2010 Jan; 5(1):49-55. PubMed ID: 20035185
[TBL] [Abstract][Full Text] [Related]
13. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
[No Abstract] [Full Text] [Related]
14. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
[TBL] [Abstract][Full Text] [Related]
16. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG
Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
[TBL] [Abstract][Full Text] [Related]
18. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
[No Abstract] [Full Text] [Related]
19. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
[TBL] [Abstract][Full Text] [Related]
20. The IASLC grading system for invasive pulmonary adenocarcinoma: a potential prognosticator for patients receiving neoadjuvant therapy.
E H; Wu J; Ren Y; Xia L; Xu L; Li S; Zhao Y; Li C; She Y; Su C; Wu C; Hou L; Zhao D; Chen C
Ther Adv Med Oncol; 2023; 15():17588359221148028. PubMed ID: 36643658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
